We are live on ! Find out more
EPZM

Epizyme, Inc

Delisted

EPZM was delisted on the 11th of August, 2022.

91 hedge funds and large institutions have $556M invested in Epizyme, Inc in 2016 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 50 increasing their positions, 11 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

355% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 11

40% more funds holding in top 10

Funds holding in top 10: 57 (+2)

15% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 13

2% more funds holding

Funds holding: 8991 (+2)

2% more capital invested

Capital invested by funds: $543M → $556M (+$12.6M)

50% less call options, than puts

Call options by funds: $2K | Put options by funds: $4K

Holders
91
Holders Change
+2
Holders Change %
+2.25%
% of All Funds
2.42%
Holding in Top 10
7
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+40%
% of All Funds
0.19%
New
15
Increased
50
Reduced
11
Closed
13
Calls
$2K
Puts
$4K
Net Calls
-$2K
Net Calls Change
-$50K
Name Holding Trade Value Shares
Change
Change in
Stake
BBA
26
Baker Bros. Advisors
New York
$2.82M
OPPM
27
Opus Point Partners Management
New York
$2.3M +$546K +53,937 +40%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$2.02M +$485K +47,951 +40%
California Public Employees Retirement System
29
California Public Employees Retirement System
California
$1.94M -$98.1K -9,700 -6%
CS
30
Candriam SCA
Luxembourg
$1.93M -$212K -21,000 -12%
JP Morgan Chase
31
JP Morgan Chase
New York
$1.86M +$1.32M +130,044 +551%
BIM
32
BlackRock Investment Management
Delaware
$1.71M +$454K +44,855 +47%
TC
33
TFS Capital
Pennsylvania
$1.68M +$649K +64,189 +86%
Charles Schwab
34
Charles Schwab
California
$1.52M +$455K +44,948 +56%
TCIM
35
TIAA CREF Investment Management
New York
$1.41M +$204K +20,124 +21%
QI
36
QS Investors
New York
$1.15M
California State Teachers Retirement System (CalSTRS)
37
California State Teachers Retirement System (CalSTRS)
California
$1.03M +$318K +31,402 +58%
Principal Financial Group
38
Principal Financial Group
Iowa
$1M -$6.99K -691 -0.8%
TA
39
Teachers Advisors
New York
$815K +$241K +23,845 +55%
Swiss National Bank
40
Swiss National Bank
Switzerland
$659K +$286K +28,300 +100%
Deutsche Bank
41
Deutsche Bank
Germany
$619K +$212K +20,953 +69%
ProShare Advisors
42
ProShare Advisors
Maryland
$572K +$95K +9,394 +25%
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$432K +$81.4K +8,045 +29%
Citigroup
44
Citigroup
New York
$424K +$305K +30,120 +617%
New York State Common Retirement Fund
45
New York State Common Retirement Fund
New York
$418K +$58.7K +5,800 +20%
MLICM
46
Metropolitan Life Insurance Company (MetLife)
New York
$377K +$106K +10,491 +51%
CS
47
Credit Suisse
Switzerland
$369K +$206K +20,327 +200%
Renaissance Technologies
48
Renaissance Technologies
New York
$356K +$297K +29,388 New
AllianceBernstein
49
AllianceBernstein
Tennessee
$343K -$164K -16,200 -36%
AL
50
Airain Ltd
Guernsey
$334K +$278K +27,519 New

EPZM Hedge Fund Activity: Q1 2016 in Review

91 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q1 2016, worth a combined $556M — up 2.3% from $543M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new EPZM positions and 13 closed out — a net gain of 2 holders — while 50 added to existing stakes and 11 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $17M. The largest seller was Lord, Abbett & Co, exiting entirely with an estimated $1.25M sold.

  • 91 institutional investors held Epizyme, Inc (EPZM) as of Q1 2016, up from 89 in Q4 2015.
  • Funds reported $556M of Epizyme, Inc stock for Q1 2016, up 2.3% quarter-over-quarter.
  • 15 funds opened new Epizyme, Inc positions in Q1 2016 and 13 closed out, a net change of +2 holders.
  • The largest Epizyme, Inc buyer in Q1 2016 was Fidelity Investments, an estimated $17M added.
  • The largest Epizyme, Inc seller in Q1 2016 was Lord, Abbett & Co, an estimated $1.25M sold.

Based on aggregated 13F filings for Q1 2016.